* Laquinimod -- Phase III Allegro study fully enrolled
* 57-57 -- Phase II/III program only to be initiated in cooperation
with partner
* RhuDex(TM) -- additional preclinical trials being performed
* ANYARA -- presentation of data in combination with established
tumor drug
* TASQ -- Phase II study proceeding as planned
* Net sales SEK 53.5 M (12.1)
* Operating loss SEK 184.6 M (loss: 202.7)
* Loss after tax SEK 181.6 M (loss: 207.7)
* Loss per share for the year was SEK 3.66 (loss: 4.47)
For further information, please contact:
Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95
Göran Forsberg
VP Investor Relations & Business Development
Tel: +46 (0)46-19 11 54
Hans Kolam
CFO
Tel: +46 (0)46-19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
This report is also available at www.activebiotech.com
